S.K. Labs VP Imprisoned Before Trial On Charges Linked To USPlabs

S.K. Labs VP Sitesh Patel was sentenced for his conviction in an April trial of single counts of conspiracy to defraud FDA and conspiracy to commit mail fraud and three counts of mail fraud. He faced up to 85 years in prison and up to $1.25m in fines.

court house

The vice president of a firm charged with making stimulant-spiked sports nutrition products for [USPlabs LLC]has been sentenced to less than a year in prison and $127,000 in penalties for his conviction on charges from a separate investigation.

Sitesh Patel, VP of S.K. Laboratories Inc., on June 6 was sentenced for his April convictions in US District Court...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

EU Industry Wants EFSA Changes To Support Innovation

 
• By 

Prominent trade groups call on the European Commission to improve risk assessment of innovative food products by making changes to processes at the European Food Safety Authority.

US FDA Clarifies Success For An NDI Notification Fits Only The Notifier’s Ingredient

Along with two instructional videos, FDA provides fact sheet detailing common problems with NDINs while supplement industry awaits guidance on two hurdles for clearing the NDIN process, providing identity information and evidence of safety for ingredients.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By 

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By 

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

More from Policy & Regulation